Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

Background Immune checkpoint therapy (ICT) prolongs survival in subsets of patients with cancer but can also trigger immune-related adverse events (irAEs) requiring treatment discontinuation. Recent studies have investigated safety of ICT rechallenge after irAEs, and evidence suggests that rechallen...

Full description

Bibliographic Details
Main Authors: Jennifer Wang, Jianjun Gao, Pavlos Msaouel, Padmanee Sharma, Nizar Tannir, Sumit K Subudhi, Eric Jonasch, Amishi Shah, Matthew T Campbell, Bilal A Siddiqui, Jinesh S Gheeya, Rohit Goswamy, Tharakeswara K Bathala, Devaki Shilpa Surasi, Sangeeta Goswami, Amado J Zurita, Paul G Corn, Ana M Aparicio, Arlene O Siefker-Radtke
Format: Article
Language:English
Published: BMJ Publishing Group 2021-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/7/e002850.full

Similar Items

Similar Items